# US 2024/0197766 A1 · Treatment of rna virus infection with a cytidine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197766 A1
- Document ID: US20240197766A1
- Status: Published application
- Kind: A1
- Application number: 18/552,615
- Filed: 2022-03-22
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Yogen Saunthararajah; Babal K. Jha; Xiaorong Gu
- Web page: https://patentgrep.com/patent/US20240197766A1

## CPC

- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/42: Oxazoles
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions, systems, kits, and methods for treating a subject with an RNA virus infection (e.g., SARS-COV-2) by administering or providing a composition comprising a cytidine deaminase inhibitor (e.g., tetrahy-drouridine or cedazuridine).

## Claims

### Claim 1

A method of treating a subject infected with an RNA virus comprising:
administering a composition to a subject, or providing said composition to said subject such that said subject administers said composition to themselves;
wherein said subject is infected with an RNA virus;
wherein said composition comprises a cytidine deaminase inhibitor.

### Claim 1 (depends on 1)

ethod of claim 1, wherein said cytidine deaminase inhibitor comprises a compound of Formula I, wherein Formula I is as follows:
or a pharmaceutically acceptable salt of the compound, wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, halo, cyano, nitro, sulfhydryl, hydroxyl, formyl, carboxyl, COO (C1 to C6 straight or branched chain alkyl), COO (C1 to C6 straight or branched chain alkenyl), COO (C1 to C6 straight or branched chain alkynyl), CO (C1 to C6 straight or branched chain alkyl), CO (C1 to C6 straight or branched chain alkenyl), CO (C1 to C6 straight or branched chain alkynyl), C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, and C1 to C6 straight or branched chain alkenoxy; wherein each occurrence of C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, or C1 to C6 straight or branched chain alkenoxy, may be independently unsubstituted or substituted with one to four substituents independently selected from the group consisting of halo, hydroxyl, cyano, nitro, formyl, carboxyl, and sulfhydryl;
and provided that when one of R1 and R2 is —H, then the other is not —H, —OH or —CH2OH.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cytidine deaminase inhibitor comprises tetrahydrouridine, cedazuridine, and/or diazepinone riboside.

### Claim 4 (depends on 1)

The method of claim 1, wherein said RNA virus is SAR2-COV-2 or other coronavirus.

### Claim 5 (depends on 1)

The method of claim 1, wherein said subject is further administered a pyrimidine synthesis inhibitor.

### Claim 6 (depends on 5)

The method of claim 5, wherein said pyrimidine synthesis inhibitor comprises teriflunomide.

### Claim 7 (depends on 5)

The method of claim 5, wherein said pyrimidine synthesis inhibitor comprises leflunomide.

### Claim 8 (depends on 1)

The method of claim 1, wherein said subject is further administered an inhibitor of viral RNA polymerase.

### Claim 9 (depends on 8)

The method of claim 8, wherein said inhibitor of viral RNA polymerase is remdesivir.

### Claim 10 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 11 (depends on 1)

The method of claim 1, wherein said subject is an animal.

### Claim 12 (depends on 1)

The method of claim 1, wherein said administering is such that said subject receives about 5-100 mg of said cytidine deaminase inhibitor per kilogram of said subject per day.

### Claim 13 (depends on 1)

The method of claim 1, wherein said administering is intravenous administration or oral administration or via said subject's airway.

### Claim 14 (depends on 1)

The method of claim 1, wherein said subject administers said composition to themselves orally, and wherein said composition comprises a pill or capsule, and wherein said subject receives about 5-100 mg of said cytidine deaminase inhibitor per kilogram of said subject per day.

### Claim 15 (depends on 1)

The method of claim 1, further comprising: administering or providing an anti-coagulant to said subject.

### Claim 16 (depends on 1)

The method of claim 1, further comprising: administering or providing a different anti-viral agent to said subject.

### Claim 17 (depends on 1)

The method of claim 1, wherein said subject is on a ventilator.

### Claim 18 (depends on 1)

The method of claim 1, wherein said composition further comprises a physiologically tolerable buffer.

### Claim 19

A system, kit, or article of manufacture comprising:
a) a composition comprising a cytidine deaminase inhibitor; and
b) a container selected from the group consisting of:
i) an airway administration device, and
ii) an orally ingestible dosage form.

### Claim 20 (depends on 19)

The system, kit, or article of manufacture of claim 19, wherein said airway administration device is a nebulizer.

### Claim 21 (depends on 19)

The system, kit, or article of manufacture of claim 19, wherein said orally ingestible dosage form is a capsule or pill that comprises an enteric coating.

### Claim 22 (depends on 19)

The system, kit, or article of manufacture of claim 19, wherein said cytidine deaminase inhibitor comprises tetrahydrouridine, cedazuridine, and/or diazepinone riboside.

### Claim 23 (depends on 19)

The system, kit, or article of manufacture of claim 19, wherein said cytidine deaminase inhibitor comprises a compound of Formula I, wherein Formula I is as follows:
or a pharmaceutically acceptable salt of the compound, wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, halo, cyano, nitro, sulfhydryl, hydroxyl, formyl, carboxyl, COO (C1 to C6 straight or branched chain alkyl), COO (C1 to C6 straight or branched chain alkenyl), COO (C1 to C6 straight or branched chain alkynyl), CO (C1 to C6 straight or branched chain alkyl), CO (C1 to C6 straight or branched chain alkenyl), CO (C1 to C6 straight or branched chain alkynyl), C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, and C1 to C6 straight or branched chain alkenoxy; wherein each occurrence of C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, or C1 to C6 straight or branched chain alkenoxy, may be independently unsubstituted or substituted with one to four substituents independently selected from the group consisting of halo, hydroxyl, cyano, nitro, formyl, carboxyl, and sulfhydryl;
and provided that when one of R1 and R2is —H, then the other is not —H, —OH or —CH2OH.

### Claim 24

A composition comprising:
a) a cytidine deaminase inhibitor; and
b) an RNA virus.

### Claim 25 (depends on 24)

The composition of claim 24, wherein said cytidine deaminase inhibitor comprises tetrahydrouridine, cedazuridine, and/or diazepinone riboside.

### Claim 26 (depends on 24)

The composition of claim 24, wherein said cytidine deaminase inhibitor comprises a compound of Formula I, wherein Formula I is as follows:
or a pharmaceutically acceptable salt of the compound, wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, halo, cyano, nitro, sulfhydryl, hydroxyl, formyl, carboxyl, COO (C1 to C6straight or branched chain alkyl), COO (C1 to C6 straight or branched chain alkenyl), COO (C1 to C6 straight or branched chain alkynyl), CO (C1 to C6 straight or branched chain alkyl), CO (C1 to C6 straight or branched chain alkenyl), CO (C1 to C6 straight or branched chain alkynyl), C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, and C1 to C6 straight or branched chain alkenoxy; wherein each occurrence of C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, or C1 to C6 straight or branched chain alkenoxy, may be independently unsubstituted or substituted with one to four substituents independently selected from the group consisting of halo, hydroxyl, cyano, nitro, formyl, carboxyl, and sulfhydryl;
and provided that when one of R1 and R2is —H, then the other is not —H, —OH or —CH2OH.

### Claim 27

An in vitro composition comprising:
a) a cytidine deaminase inhibitor; and
b) an inhibitor of pyrimidine synthesis.

### Claim 28

A system or kit comprising:
a) a composition a cytidine deaminase inhibitor; and
b) instructions for treating a subject with said composition, wherein said subject is infected with: an RNA virus.

### Claim 29

An article of manufacture comprising an orally ingestible pill or capsule, wherein said orally ingestible pill or capsule comprises:
a) a composition comprising a cytidine deaminase inhibitor; and
b) an enteric coating which surrounds said composition.

### Claim 30 (depends on 29)

The article of manufacture of claim 29, wherein said pill or capsule comprises a capsule, wherein said capsule comprises a softgel.

### Claim 31 (depends on 30)

The article of manufacture of claim 30, wherein said softgel comprises gelatin.

### Claim 32 (depends on 29)

The article of manufacture of claim 29, wherein said cytidine deaminase inhibitor comprises tetrahydrouridine, cedazuridine, and/or diazepinone riboside.

### Claim 33 (depends on 29)

The article of manufacture of claim 29, wherein said cytidine deaminase inhibitor comprises a compound of Formula I, wherein Formula I is as follows:
or a pharmaceutically acceptable salt of the compound, wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, halo, cyano, nitro, sulfhydryl, hydroxyl, formyl, carboxyl, COO (C1 to C6 straight or branched chain alkyl), COO (C1 to C6 straight or branched chain alkenyl), COO (C1 to C6 straight or branched chain alkynyl), CO (C1 to C6 straight or branched chain alkyl), CO (C1 to C6 straight or branched chain alkenyl), CO (C1 to C6 straight or branched chain alkynyl), C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, and C1 to C6 straight or branched chain alkenoxy; wherein each occurrence of C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, or C1 to C6 straight or branched chain alkenoxy, may be independently unsubstituted or substituted with one to four substituents independently selected from the group consisting of halo, hydroxyl, cyano, nitro, formyl, carboxyl, and sulfhydryl;
and provided that when one of R1 and R2is —H, then the other is not —H, —OH or —CH2OH.
